Earnings Releases·Nov 5, 2026, 7:01 AM ET

Teleflex Incorporated — Third Quarter 2026 Earnings Summary

Q3 revenue from continuing operations reached $567.8 million (up 0.2% YoY), while GAAP diluted EPS turned positive at $1.30 versus a $1.32 loss in the prior year; adjusted diluted EPS rose to $2.63 from $1.89.
Full-year 2026 guidance was adjusted to reflect a reduced GAAP revenue growth range of 13.2%–14.2% due to FX impacts, while GAAP and adjusted EPS guidance ranges were increased to $2.84–$3.09 and $7.50–$7.75, respectively.
Strategic progress includes the completed $1.5 billion OEM divestiture, ongoing sale of Acute Care and Interventional Urology businesses, and a $350 million share repurchase program with $400 million remaining.
Management anticipates a significant earnings step-up in 2027 following the completion of the Vascular Intervention integration and strategic divestitures, with segment performance showing growth in Vascular (+4.7%) and Surgical (+4.2%) and a return to modest growth in Interventional.